Skip to main content
SpringerLink
Log in

Pharmacological Therapy for Cardiovascular Disease

Current and Emerging Therapies

  • Chapter
Therapeutic Lipidology

Part of the book series: Contemporary Cardiology ((CONCARD))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Thom T, Haase N, Rosamond W, et al. for the Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2006 update. Circulation 2006;113:e85–e151.

    Google Scholar 

  2. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol 2005;96:556–563.

    Article  PubMed  Google Scholar 

  3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.

    Google Scholar 

  4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383–1389.

    Google Scholar 

  5. Packard CJ, Shepherd J, Cobbe SM, et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCPOS). Circulation 1998;97:1440–1445.

    Google Scholar 

  6. Downs JR, Clearfield M, Weiss S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615–1622.

    Google Scholar 

  7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22.

    Article  Google Scholar 

  8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  9. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.

    Article  Google Scholar 

  10. Shepherd J, Blauw GJ, Murphy MD, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  11. PDR 2006. http://www.pdr.net (accessed September 17, 2006).

    Google Scholar 

  12. Holdaas H, Fellstrom B, Jardine AG, et al. for the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024–2031.

    Article  PubMed  CAS  Google Scholar 

  13. Newman CG, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670–676.

    Article  PubMed  CAS  Google Scholar 

  14. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  15. Colhoun HM, Thomason MJ, Mackness MI, et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002;19:201–211.

    Article  PubMed  CAS  Google Scholar 

  16. LaRosa JC, Grundy SM, Waters DD, et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–1435.

    Article  PubMed  CAS  Google Scholar 

  17. Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized control trial. JAMA 2005;294:2437–2445.

    Article  PubMed  CAS  Google Scholar 

  18. Jones PH, Davidson MH, Stein EA, et al. for STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152–160.

    Article  PubMed  CAS  Google Scholar 

  19. Fellstrom B, Holdaas H, Jardine AG, et al. for the Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004;66:1549–1555.

    Article  PubMed  Google Scholar 

  20. Catapano AL. Ezitimbe: a selective inhibitor of cholesterol absorption: Eur Heart J 1002;Suppl 3 (Suppl E):E6–E10.

    Google Scholar 

  21. van Heek M, France DF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157–163.

    PubMed  Google Scholar 

  22. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748–1754.

    Article  PubMed  Google Scholar 

  23. Knopp RH, Bays H, Manion CV, et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins [abstract]. Atherosclerosis 2001;2(Suppl):90.

    Google Scholar 

  24. Davis HR, Compton DS, Hoos L, et al. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption. Eur Heart J 2000;21(Suppl):636[Abstract P3500].

    Google Scholar 

  25. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209–1230.

    Article  PubMed  CAS  Google Scholar 

  26. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90,1092–1097.

    Article  PubMed  CAS  Google Scholar 

  27. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of SCH 58235 on the activity of drug metabolizing enzymes in vivo [abstract]. Clin Pharmacol Ther 2000;67:152 [Abstract PIII-43].

    Google Scholar 

  28. Zhu Y, Statkevich P, Kosoglou T, et al. Lack of a pharmacokinetic interaction between ezetimibe and atorvastatin [abstract]. Clin Pharmacol Ther 2001;69:68 [Abstract PIII-15].

    Google Scholar 

  29. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309–319.

    Article  PubMed  CAS  Google Scholar 

  30. Reyderman L, Kosoglou T, Statkevich P, et al. No pharmacokinetic drug interaction between ezetimibe and lovastatin [abstract]. Clin Pharmacol Ther 2001;69:66 [Abstract PIII-8].

    Article  Google Scholar 

  31. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary. J Am Coll Cardiol 2002;40:2125–2134.

    Article  PubMed  CAS  Google Scholar 

  32. Ballantyne C, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409–2415.

    Article  PubMed  CAS  Google Scholar 

  33. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418–424.

    Article  PubMed  CAS  Google Scholar 

  34. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717–728.

    Article  PubMed  CAS  Google Scholar 

  35. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol in press.

    Google Scholar 

  36. Statkevich P, Reyderman L, Kosoglou T, et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide [abstract]. Clin Pharmacol Ther 2001;69:67 [Abstract PIII-12].

    Google Scholar 

  37. Kosoglou T, Statkevich P, Bauer KS, et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin [abstract]. AAPS Pharm Sci 2.

    Google Scholar 

  38. Keung AC, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives [abstract]. Clin Pharmacol Ther 2001;69:55. Abstract PII-89001;3(Suppl 3):[serial online].

    Google Scholar 

  39. Bauer KS, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin [abstract]. Clin Pharmacol Ther 2001;69:5 [Abstract PI-15].

    Google Scholar 

  40. Krishna G, Kosoglou T, Ezzet F, et al. Effect of cimetidine on the pharmacokinetics of ezetimibe [abstract]. AAPS Pharm Sci 2001;3(Suppl 3):[serial online].

    Google Scholar 

  41. Courtney RD, Kosoglou T, Statkevich P, et al. Effect of antacid on the pharmacokinetics of ezetimibe. Clin Pharmacol Ther 2002;71:80.

    Google Scholar 

  42. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365–374.

    Article  Google Scholar 

  43. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323: 1289–1298.

    Article  PubMed  CAS  Google Scholar 

  44. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893–1900.

    Article  PubMed  CAS  Google Scholar 

  45. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020–2028.

    PubMed  CAS  Google Scholar 

  46. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000;2:36–46.

    Article  PubMed  CAS  Google Scholar 

  47. Capuzzi DM, Buyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long term study. Am J Cardiol 1998;82:74U–81U.

    Article  PubMed  CAS  Google Scholar 

  48. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255.

    Article  PubMed  CAS  Google Scholar 

  49. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.

    Article  Google Scholar 

  50. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharm 1991;40(Suppl):S49–S51.

    Article  Google Scholar 

  51. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scan 1988;223:405–418.

    Google Scholar 

  52. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–1592.

    Article  PubMed  Google Scholar 

  53. Gray DR, Morgan T, Chretien SD, et al. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994;121:252–258.

    PubMed  CAS  Google Scholar 

  54. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737–743.

    Article  PubMed  CAS  Google Scholar 

  55. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263–1270.

    Article  PubMed  CAS  Google Scholar 

  56. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568–1576.

    Article  PubMed  CAS  Google Scholar 

  57. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042–1051.

    Article  PubMed  CAS  Google Scholar 

  58. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density lipoprotein Intervention Trial h(VA-HIT). Arch Intern Med 2002;162:2597–2604.

    Article  PubMed  CAS  Google Scholar 

  59. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154–1160.

    Article  PubMed  CAS  Google Scholar 

  60. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779–1785.

    PubMed  CAS  Google Scholar 

  61. Keech A, Simes RJ, Barter P, et al. for FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005;366:1849–1861.

    Article  PubMed  CAS  Google Scholar 

  62. Nestel PJ. Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr 2000;71:228S–231S.

    PubMed  CAS  Google Scholar 

  63. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006;98:27i–33i.

    Article  PubMed  CAS  Google Scholar 

  64. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(5 Suppl):1645S–1654S.

    PubMed  CAS  Google Scholar 

  65. Maki KC, Van Elswyk ME, McCarthy D, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr 2005;24:189–199.

    PubMed  Google Scholar 

  66. Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol 1997;80: 797–798.

    Article  PubMed  CAS  Google Scholar 

  67. Barter PJ, Brewer HB JR, Chapman JM, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160–167.

    Article  PubMed  Google Scholar 

  68. Bays H, McKenney JM, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 2005;3:789–820.

    Article  PubMed  CAS  Google Scholar 

  69. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Atheroscler Thromb Vasc Biol 2004;24:490–497.

    Article  CAS  Google Scholar 

  70. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;250:1505–1515.

    Article  Google Scholar 

  71. Davidson MH, Robinson JG. Management of elevated LDL.

    Google Scholar 

  72. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005;78(2):154–167.

    Article  PubMed  CAS  Google Scholar 

  73. TriCor [package insert]. Abbott Laboratories; 2004.

    Google Scholar 

  74. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001;69:340–345.

    Article  PubMed  CAS  Google Scholar 

  75. Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000;40:316–323.

    Article  PubMed  CAS  Google Scholar 

  76. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122–129.

    Article  PubMed  CAS  Google Scholar 

  77. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685–691.

    Article  PubMed  CAS  Google Scholar 

  78. Abbott Laboratories. Data on file; 2005.

    Google Scholar 

  79. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90(Suppl):50K–60K.

    Article  Google Scholar 

  80. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280–1287.

    Article  PubMed  CAS  Google Scholar 

  81. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459–471.

    Article  PubMed  CAS  Google Scholar 

  82. Bergman AJ, Murphy G, Burke J. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054–1062.

    Article  PubMed  CAS  Google Scholar 

  83. Davidson MH, Robinson JG. Lipid-lowering effects of statins: a comparative review. Expert Opin Pharmacother 2006;7:1701–1714.

    Article  PubMed  CAS  Google Scholar 

  84. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712–1719.

    Article  PubMed  CAS  Google Scholar 

  85. Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004;47:73–104.

    Article  PubMed  CAS  Google Scholar 

  86. Pegorier JP, Le May C, Girard J. Control of gene expression by fatty acids. J Nutr 2004;134: 2444S–2449S.

    PubMed  CAS  Google Scholar 

  87. Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995;76:80A–83A.

    Article  PubMed  CAS  Google Scholar 

  88. Fruchart JC. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. American Journal of Cardiology. 88(12A):24N–29N, 2001.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Michael H. Davidson MD,FACC,FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Director of Preventive Cardiology, Rush University Medical Center Radiant Research, Chicago, IL

    Michael H. Davidson MD,FACC,FACP

  2. Director of Preventive Cardiology, Sterling Rock Falls Clinic Chief of Medicine CGH Medical Center Clinical Associate Professor, University of Illinois College of Medicine, Peoria, IL

    Peter P. Toth MD,PhD,FAAP,FICA,FAHA,FCCP,FACC

  3. Southern Illinois University School of Medicine, Springfield, IL

    Peter P. Toth MD,PhD,FAAP,FICA,FAHA,FCCP,FACC

  4. Chief Science Officer,Provident Clinical Research, Bloomington, IN

    Kevin C. Maki PhD

  5. Weill Cornell Medical College, New York, NY

    Antonio M. Gotto Jr MD,DPhil

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Davidson, M.H. (2007). Pharmacological Therapy for Cardiovascular Disease. In: Davidson, M.H., Toth, P.P., Maki, K.C., Gotto, A.M. (eds) Therapeutic Lipidology. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-533-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-533-6_7

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-551-4

  • Online ISBN: 978-1-59745-533-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation